Exelon / Prometax (rivastigmine) - Important Safety Information from Novartis as approved by the Irish Medicines Board

Notice type: 3rd Party Publications

Date: 04/05/2010

 

Problem Or Issue:
Important Safety Information communication from Novartis on the inappropriate use of and medication errors associated with Exelon® / Prometax® transdermal patch.

Important Safety Information - Exelon / Prometax (rivastigmine)


« Back